大剂量艾司奥美拉唑镁对幽门螺杆菌相关性胃炎的治疗效果分析
|
摘要
目的探讨大剂量艾司奥美拉唑镁治疗幽门螺杆菌相关性胃炎的临床效果。方法选择2016年6月至2017年5月于本院就诊的幽门螺杆菌相关性胃炎患者120例为研究对象,根据艾司奥美拉唑镁治疗剂量不同将其分为高剂量组(62例)和标准剂量组(58例),高剂量组患者予以40 mg艾司奥美拉唑镁肠溶片,2次/d;标准剂量组患者予以20 mg艾司奥美拉唑镁肠溶片,2次/d;两组疗程均为2周,比较两组患者治疗后的临床效果及临床症状改善情况。随访6个月,比较两组患者幽门螺杆菌清除率、复发率及不良反应发生率。结果高剂量组患者治疗总有效率显著高于标准剂量组(P <0.05);治疗后,高剂量组患者临床症状改善情况显著优于标准剂量组(P <0.05),幽门螺杆菌清除率显著高于标准剂量组(P <0.05),复发率显著低于标准剂量组(P <0.05)。两组患者不良反应发生率无显著差异(P> 0.05)。结论大剂量艾司奥美拉唑镁可显著改善幽门螺杆菌相关性胃炎患者的临床症状,提高幽门螺杆菌清除率,降低不良反应发生率,值得临床推广。
Objective To investigate the clinical effect of high dose Esomeprazole magnesium in the treatment of Helicobacter pylori related gastritis. Method 120 patients with Helicobacter pylori related gastritis who were admitted to our hospital from June 2016 to May 2017 were selected as the study subjects. According to the different doses of Esomeprazole magnesium, they were randomly divided into high-dose group(62 cases) and standard dose group(58 cases). Patients in high-dose group were given 40 mg Esomeprazole magnesium twice a day. Patients in standard dose group were given 20 mg Esomeprazole magnesium twice a day; both groups patients were treated for 2 weeks, the clinical effect and improvement of clinical symptoms were compared between the two groups. Patients were followed up for 6 months to compare the Helicobacter pylori clearance rate, recurrence rate and incidence of adverse reactions between the two groups. Result The total effective rate in high-dose group was significantly higher than that in standard dose group(P < 0.05). After treatment, the improvement of clinical symptoms in high-dose group was significantly better than that in standard dose group(P < 0.05), the clearance rate of Helicobacter pylori was significantly higher than that in standard dose group(P < 0.05), and the recurrence rate was significantly lower than that in standard dose group(P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P > 0.05). Conclusion High dose of Esomeprazole magnesium can significantly improve the clinical symptoms of patients with Helicobacter pylori related gastritis, improve the clearance rate of Helicobacter pylori, and reduce adverse reactions, which is worthy of clinical promotion.
Objective To investigate the clinical effect of high dose Esomeprazole magnesium in the treatment of Helicobacter pylori related gastritis. Method 120 patients with Helicobacter pylori related gastritis who were admitted to our hospital from June 2016 to May 2017 were selected as the study subjects. According to the different doses of Esomeprazole magnesium, they were randomly divided into high-dose group(62 cases) and standard dose group(58 cases). Patients in high-dose group were given 40 mg Esomeprazole magnesium twice a day. Patients in standard dose group were given 20 mg Esomeprazole magnesium twice a day; both groups patients were treated for 2 weeks, the clinical effect and improvement of clinical symptoms were compared between the two groups. Patients were followed up for 6 months to compare the Helicobacter pylori clearance rate, recurrence rate and incidence of adverse reactions between the two groups. Result The total effective rate in high-dose group was significantly higher than that in standard dose group(P < 0.05). After treatment, the improvement of clinical symptoms in high-dose group was significantly better than that in standard dose group(P < 0.05), the clearance rate of Helicobacter pylori was significantly higher than that in standard dose group(P < 0.05), and the recurrence rate was significantly lower than that in standard dose group(P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P > 0.05). Conclusion High dose of Esomeprazole magnesium can significantly improve the clinical symptoms of patients with Helicobacter pylori related gastritis, improve the clearance rate of Helicobacter pylori, and reduce adverse reactions, which is worthy of clinical promotion.
引文
[1]刘文忠.“幽门螺杆菌胃炎京都全球共识”解读[J].胃肠病学,2015,20(8):449-455.
[2]黄勤,房静远,于成功,等.慢性胃炎的临床与病理学诊断进展[J].胃肠病学,2013,18(2):65-70.
[3]彭罕鸣,梅红,王宝香.含益生菌的四联疗法对幽门螺杆菌的疗效[J].中国医师杂志,2015,24(8):265-267.
[4]俞文,艾尼·阿布都热依木,雪来提·艾孜木,等.不同剂量艾司奥美拉唑镁为基础的四联方案治疗248例维吾尔族幽门螺杆菌性胃炎的疗效观察[J].中华消化杂志,2017,17(3):620-624.
[5]中华医学会消化病学分会幽门螺杆菌学组.幽门螺杆菌胃炎京都全球共识研讨会纪要[J].中华消化杂志,2016,36(1):53-57.
[6]赵建业,朱春平,李兆申.血清胃蛋白酶原、胃泌素-17、幽门螺杆菌抗体检测对萎缩性胃炎和胃癌的诊断价值[J].胃肠病学,2016,21(6):376-379.
[7]张丽娜,高鹏.探讨14C尿素呼气试验检测幽门螺旋杆菌[J].中国实用医药,2011,6(1):91-94.
[8]楼晓军,王彩花,朱永良,等.幽门螺杆菌唾液测试板与14C-尿素呼气试验检测幽门螺杆菌感染的比较[J].实用医学杂志,2011,27(13):2356-2358.
[9]赵宇阳,李慧,张艳,等.胃及口腔幽门螺杆菌感染与慢性胃炎的相关性分析[J].中国实验诊断学,2018,51(3):308-310.
[10]周伟新,王建蔚,马东升.海尔曼螺杆菌与幽门螺杆菌相关性胃炎的临床病理特征分析[J].中国医药科学,2018,51(5):238-239.
[11]王永理,王阳,王学琦.中西医结合治疗幽门螺杆菌阳性胃炎46例[J].中国中西医结合消化杂志,2013,16(12):837-838.
[12]李霞.布拉酵母菌散荆花胃康胶丸联合标准四联疗法治疗幽门螺杆菌相关性胃炎及十二指肠溃疡疗效观察[J].中国药物与临床,2018,51(4):308-310.
[13]黄静娟,李树斌.中西药联合治疗幽门螺杆菌感染慢性胃炎的临床观察[J].陕西中医,2016,51(9):238-239.
[14]孔繁雯.慢性胃炎与幽门螺杆菌感染的关系探讨[J].中国保健营养,2017,16(21):837-838.
[15]胡伏莲.重视幽门螺杆菌感染根除治疗中的几个问题[J].中华医学杂志,2013,93(44):3489-3492.
[16]王瑜.幽门螺杆菌不同方案根除效果与体外抗生素耐药性研究[D].石家庄:河北医科大学,2009.
[17]唐惠林,张婷,翟所迪.CYP2C19基因多态性对质子泵抑制剂补救疗法根除幽门螺旋杆菌疗效影响的荟萃分析[J].中国医院药学杂志,2013,33(18):1520-1524.
[18]罗军波,徐雄良,秦应飞,等.艾司奥美拉唑镁肠溶多颗粒释药胶囊的研究[J].中国药学杂志,2015,50(9):789-792.
[19]高小玲,靖慧军,郭文峰,等.奥美拉唑体内外给药对壁细胞H+-K+-ATP酶活性的影响[J].世界中西医结合杂志,2014,9(4):365-367.
[20]李潇,薛艳,周丽雅.幽门螺杆菌感染复发研究进展[J].中华消化杂志,2015,35(10):713-714.
[21]朱文杰.胃镜下高频电凝联合幽门螺杆菌根除治疗疣状胃炎的疗效观察[J].中国现代药物应用,2018,51(6):238-239.
[22]郭永华.艾司奥美拉唑与奥美拉唑治疗幽门螺杆菌相关性胃溃疡疗效比较[J].临床合理用药,2017,10(9A):75-77.
[23]王澍琴,薄艳萍,苏爱平.以艾司奥美拉唑为基础四联疗法对Hp阳性十二指肠溃疡的疗效观察[J].中国现代医生,2017,55(32):103-105.
[2]黄勤,房静远,于成功,等.慢性胃炎的临床与病理学诊断进展[J].胃肠病学,2013,18(2):65-70.
[3]彭罕鸣,梅红,王宝香.含益生菌的四联疗法对幽门螺杆菌的疗效[J].中国医师杂志,2015,24(8):265-267.
[4]俞文,艾尼·阿布都热依木,雪来提·艾孜木,等.不同剂量艾司奥美拉唑镁为基础的四联方案治疗248例维吾尔族幽门螺杆菌性胃炎的疗效观察[J].中华消化杂志,2017,17(3):620-624.
[5]中华医学会消化病学分会幽门螺杆菌学组.幽门螺杆菌胃炎京都全球共识研讨会纪要[J].中华消化杂志,2016,36(1):53-57.
[6]赵建业,朱春平,李兆申.血清胃蛋白酶原、胃泌素-17、幽门螺杆菌抗体检测对萎缩性胃炎和胃癌的诊断价值[J].胃肠病学,2016,21(6):376-379.
[7]张丽娜,高鹏.探讨14C尿素呼气试验检测幽门螺旋杆菌[J].中国实用医药,2011,6(1):91-94.
[8]楼晓军,王彩花,朱永良,等.幽门螺杆菌唾液测试板与14C-尿素呼气试验检测幽门螺杆菌感染的比较[J].实用医学杂志,2011,27(13):2356-2358.
[9]赵宇阳,李慧,张艳,等.胃及口腔幽门螺杆菌感染与慢性胃炎的相关性分析[J].中国实验诊断学,2018,51(3):308-310.
[10]周伟新,王建蔚,马东升.海尔曼螺杆菌与幽门螺杆菌相关性胃炎的临床病理特征分析[J].中国医药科学,2018,51(5):238-239.
[11]王永理,王阳,王学琦.中西医结合治疗幽门螺杆菌阳性胃炎46例[J].中国中西医结合消化杂志,2013,16(12):837-838.
[12]李霞.布拉酵母菌散荆花胃康胶丸联合标准四联疗法治疗幽门螺杆菌相关性胃炎及十二指肠溃疡疗效观察[J].中国药物与临床,2018,51(4):308-310.
[13]黄静娟,李树斌.中西药联合治疗幽门螺杆菌感染慢性胃炎的临床观察[J].陕西中医,2016,51(9):238-239.
[14]孔繁雯.慢性胃炎与幽门螺杆菌感染的关系探讨[J].中国保健营养,2017,16(21):837-838.
[15]胡伏莲.重视幽门螺杆菌感染根除治疗中的几个问题[J].中华医学杂志,2013,93(44):3489-3492.
[16]王瑜.幽门螺杆菌不同方案根除效果与体外抗生素耐药性研究[D].石家庄:河北医科大学,2009.
[17]唐惠林,张婷,翟所迪.CYP2C19基因多态性对质子泵抑制剂补救疗法根除幽门螺旋杆菌疗效影响的荟萃分析[J].中国医院药学杂志,2013,33(18):1520-1524.
[18]罗军波,徐雄良,秦应飞,等.艾司奥美拉唑镁肠溶多颗粒释药胶囊的研究[J].中国药学杂志,2015,50(9):789-792.
[19]高小玲,靖慧军,郭文峰,等.奥美拉唑体内外给药对壁细胞H+-K+-ATP酶活性的影响[J].世界中西医结合杂志,2014,9(4):365-367.
[20]李潇,薛艳,周丽雅.幽门螺杆菌感染复发研究进展[J].中华消化杂志,2015,35(10):713-714.
[21]朱文杰.胃镜下高频电凝联合幽门螺杆菌根除治疗疣状胃炎的疗效观察[J].中国现代药物应用,2018,51(6):238-239.
[22]郭永华.艾司奥美拉唑与奥美拉唑治疗幽门螺杆菌相关性胃溃疡疗效比较[J].临床合理用药,2017,10(9A):75-77.
[23]王澍琴,薄艳萍,苏爱平.以艾司奥美拉唑为基础四联疗法对Hp阳性十二指肠溃疡的疗效观察[J].中国现代医生,2017,55(32):103-105.